I agree that this site is using cookies. You can find further informations here.
X
Salutari, V.
50  results:
Search for persons X
?
1

60P Exploration of homologous recombination deficiency test..:

Camarda, F. ; Marino, I. ; Giacomini, F....
ESMO Open.  9 (2024)  - p. 103567 , 2024
Link: https://doi.org/10.1016/..
 
?
2

28P Real-life efficacy and safety of cemiplimab in advanced..:

Tuninetti, V. ; Virano, E. ; Salutari, V....
ESMO Open.  9 (2024)  - p. 103528 , 2024
Link: https://doi.org/10.1016/..
 
?
3

84P Lack of diversity in clinical trials leading to Food an..:

Giudice, E. ; Sganga, S. ; Rapisarda, E....
ESMO Open.  9 (2024)  - p. 103544 , 2024
Link: https://doi.org/10.1016/..
 
?
4

29P fT3/fT4 ratio, systemic inflammation and skeletal muscl..:

Tuninetti, V. ; Virano, E. ; Calvo, A....
ESMO Open.  9 (2024)  - p. 103529 , 2024
Link: https://doi.org/10.1016/..
 
?
5

43O Durvalumab (D) + carboplatin/paclitaxel (CP) + bevacizu..:

Trillsch, F. ; Okamoto, A. ; Kim, J-W....
ESMO Open.  9 (2024)  - p. 103550 , 2024
Link: https://doi.org/10.1016/..
 
?
6

MITO END-3: efficacy of avelumab immunotherapy according to..:

Pignata, S. ; Califano, D. ; Lorusso, D....
Annals of Oncology.  35 (2024)  7 - p. 667-676 , 2024
Link: https://doi.org/10.1016/..
 
?
7

174P Endocrine disruptors and life STILe in patients carryi..:

Fabi, A. ; Franco, A. ; Cordisco, E. Lucci...
ESMO Open.  8 (2023)  1 - p. 101451 , 2023
Link: https://doi.org/10.1016/..
 
?
8

42P Efficacy of maintenance with PARPi in advanced ovarian ..:

Marchetti, C. ; Fagotti, A. ; Cassani, C....
ESMO Open.  8 (2023)  1 - p. 100822 , 2023
Link: https://doi.org/10.1016/..
 
?
9

52P Real-world data of niraparib in platinum sensitive rela..:

Musacchio, L. ; Palluzzi, E. ; Lauria, R....
ESMO Open.  8 (2023)  1 - p. 100832 , 2023
Link: https://doi.org/10.1016/..
 
?
10

MO-0049 SBRT in ovary cancer patients progressing within PA..:

Macchia, G. ; Campitelli, M. ; Russo, D....
Radiotherapy and Oncology.  182 (2023)  - p. S16-S17 , 2023
Link: https://doi.org/10.1016/..
 
?
11

Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thr..:

Oliva E. N ; Riva M ; Niscola P...
info:eu-repo/semantics/altIdentifier/pmid/37294914.  , 2023
Link: https://hdl.handle.net/1..
 
?
12

Therapeutic Potential of Tisotumab Vedotin in the Treatment..:

Agostinelli V ; Musacchio L ; Camarda F...
https://www.dovepress.com/therapeutic-potential-of-tisotumab-vedotin-in-the-treatment-of-recurre-peer-reviewed-fulltext-article-CMAR.  , 2023
Link: https://doaj.org/article..
 
?
13

AVALON: The Italian cohort study on real-life efficacy of h..:

Todisco E ; Papayannidis C ; Fracchiolla N...
info:eu-repo/semantics/altIdentifier/pmid/36692409.  , 2023
Link: https://hdl.handle.net/1..
 
?
14

Combining PARP inhibition and immune checkpoint blockade in..:

Musacchio, L. ; Cicala, C.M. ; Camarda, F....
ESMO Open.  7 (2022)  4 - p. 100536 , 2022
Link: https://doi.org/10.1016/..
 
?
15

Combining PARP inhibition and immune checkpoint blockade in..:

Musacchio, L ; Cicala, C.M ; Camarda, F...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294238/.  , 2022
Link: http://www.ncbi.nlm.nih...
 
1-15